With a compound annual growth rate (CAGR) of 6.8%, the global attenuated vaccines market share is predicted to rise from US$ 4,451.7 million in 2022 to US$ 9,305.8 million by 2032.
A attenuated immunisation aids in the prevention of illnesses such as retroviral infections, measles, TB, yellow fever, and so forth. Furthermore, it has been documented that antibiotic overuse is linked to the resurgence of the aforementioned illnesses. This is an additional driver driving the market for attenuated vaccines throughout the forecast period.
The present scenario is also such that pharmaceuticals are going for a number of clinical trials throughout the year. This factor is catalyzing the attenuated vaccines market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14844
Live attenuated vaccines get prepared by weakening viral or bacterial stains by making use of stable mutations. The technology does not cause microorganisms to perish; but eliminates their disease-causing ability.
At the same time, the fact that initial cost associated with development of these vaccines is high can’t be ignored. This factor could restrain the attenuated vaccines market going forward.
Future Market Insights has walked through these facts with future prospects in its latest market study entitled ‘Attenuated Vaccines Market’. It has its indigenous team of analysts and consultants to look through an eagle’s eye view in its primary, secondary, and tertiary modes of research.
“With infectious diseases on the rise, the global attenuated vaccines market is likely to grow on a stupendous note in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from Attenuated Vaccines Market
- North America holds more than 30% of the overall market share extensive research being conducted regarding treatments against infectious diseases. Additionally, the governments are taking initiatives regarding vaccination against influenza. As of May 2022, ~65% of the localites have been vaccinated.
- The Asia-Pacific is expected to grow at the quickest rate in the attenuated vaccines market going forward. This could be attributed to immunization programs being conducted on an exorbitant note in the regions like India. Herein, Mission Indradhanush is into operation since the year 2014; which does cover almost 27 Million infants every single year. As a part of this programme, novel vaccines inclusive of PCV (Pneumococcal Conjugate Vaccines) and RVV (Rotavirus Vaccines) were covered.
Competitively Attenuated Vaccines
- Valneva SE, in May 2022, did announce completing lot-to-lot Phase 3 trial of VLA1553 (single-shot chikungunya live attenuated vaccines candidate). The ultimate analysis encloses 6-month follow-up data. Topline results were recorded in December 2021.
- Bavarian Nordic, in May 2022, developed Jynneos – a live attenuated vaccine that renders immunity against monkeypox and smallpox. Plus, symptoms could be managed with hydration therapy and antibiotics.
- Codagenix, Inc., in May 2022, collaborated with Serum Institute of India Pvt. Ltd. for dosing its UK-based Phase 1 clinical trial for evaluating usage of the former’s new live-attenuated, intranasal vaccine ‘CoviLiv’. It acts as a booster to healthy adults after getting vaccinated for Covid-19.
What does the Report say?
- The research study is based on vaccines type (monovalent attenuated vaccines and multivalent attenuated vaccines), by indication (attenuated vaccines for influenza, attenuated vaccines for MMR (measles, mumps & rubella), attenuated vaccines for polio, attenuated vaccines for chickenpox, attenuated vaccines for shingles, attenuated vaccines for rotavirus, and attenuated vaccines for other indications), by route of administration (intramuscular attenuated vaccines administration, subcutaneous attenuated vaccines administration, oral attenuated vaccines administration, intranasal attenuated vaccines administration, and intravenous attenuated vaccines administration), by age group (attenuated vaccines for paediatrics, attenuated vaccines for adolescents, attenuated vaccines for adults, and attenuated vaccines for geriatric patients), and by end-user (attenuated vaccines for hospitals, attenuated vaccines for clinics, and attenuated vaccines for other end-users).
- With governmental organizations emphasizing on immunization, the global attenuated vaccines market is expected to grow on a grand note going forward.
By Key Players
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Sanofi
- Astellas Pharma
- Johnson & Johnson
- CSL Limited
- Serum Institute of India Pvt. Ltd.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14844
Key Segments Covered in the Attenuated Vaccines Market Report
Attenuated Vaccines Market by Vaccines Type:
- Monovalent Attenuated Vaccines
- Multivalent Attenuated Vaccines
Attenuated Vaccines Market by Indication:
- Attenuated Vaccines for Influenza
- Attenuated Vaccines for Measles, Mumps & Rubella (MMR)
- Attenuated Vaccines for Polio
- Attenuated Vaccines for Chickenpox
- Attenuated Vaccines for Shingles
- Attenuated Vaccines for Rotavirus
- Attenuated Vaccines for Other Indications
Attenuated Vaccines Market by Route of Administration:
- Intramuscular Attenuated Vaccines Administration
- Subcutaneous Attenuated Vaccines Administration
- Oral Attenuated Vaccines Administration
- Intranasal Attenuated Vaccines Administration
- Intravenous Attenuated Vaccines Administration
Attenuated Vaccines Market by Age Group:
- Attenuated Vaccines for Pediatrics
- Attenuated Vaccines for Adolescents
- Attenuated Vaccines for Adults
- Attenuated Vaccines for Geriatric Patients
Attenuated Vaccines Market by End User:
- Attenuated Vaccines for Hospitals
- Attenuated Vaccines for Clinics
- Attenuated Vaccines for Other End Users
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
